Back

Characterisation of the pharmacokinetic and pharmacodynamic relationship of milvexian in total knee replacement patients

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel anticoagulants and indications Anticoagulants ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Wangda Zhou

Spring House (United States of America)

7 More presentations in this session

Presentation thumbnail
Factor XI activity in ST-segment elevation myocardial infarction
Doctor M. Spagnolo (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials
Doctor M. Maqsood (Houston, US)
Abstract Slides Video
Presentation thumbnail
Direct Oral Anticoagulants versus Vitamin K Antagonists for the management of left ventricular thrombus after myocardial infarction: A meta-analysis
Doctor C. Gogos (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: a post-hoc sub-study of ETNA-AF-Europe
Doctor T. de Vries (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Unfractionated heparin or low molecular weight heparin in patients with acute pulmonary embolism: a meta-analysis of randomized controlled trials
Doctor M. Maqsood (Houston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel anticoagulants and indications

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Factor XI inhibitors in early clinical trials: a meta-analysis
thumbnail
Congress Presentation
Targeting factor XI: innovations in anticoagulation
thumbnail
Congress Presentation
Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources